MOTS-c and NAD+ together support the cellular adaptation loop that metabolic stress and age can erode. MOTS-c is a peptide encoded in mitochondrial DNA that tells cells to build more capacity and shift toward fat as fuel — the same signal endurance exercise produces. NAD+ is the electron-carrier currency cells need to execute those instructions: ATP production, stress-response gene changes, and DNA repair. Paired, they close the loop at both ends.
Plasma NAD+ falls substantially with age and chronic load. MOTS-c levels track with metabolic flexibility: the people handling glucose and fat well tend to have more of the signal, while sedentary stress, insulin resistance, and inflammatory load push it down. In obese middle-aged adults, an oral NAD+ precursor raised NAD+ levels but did not improve insulin resistance or other metabolic endpoints — substrate without enough adaptive signal to act on it. The case for pairing lives in that gap: cells need both the signal and the currency.
This protocol is built for populations whose adaptation loop is under pressure: adults with unexplained fatigue, GLP-1 users feeling the energy drag side-effect, people with post-viral or long-COVID energy collapse, and active individuals hitting a ceiling with training. What these share is a strained adaptation loop — the signal weakening, the substrate depleting, or both.
| At a Glance | |
|---|---|
| Dosage | NAD+ 100–250 mg IM, 2–3× per week. SubQ can work at lower or split doses. MOTS-c 5–10 mg SubQ, 2–3× per week. |
| Protocol | 12 weeks, three phases (loading / build / maintain). Morning NAD+; MOTS-c 30–60 min before zone-2 cardio. |
| Results timeline | NAD+ support may shift felt energy within 1–2 weeks, sometimes within days; MOTS-c-driven adaptation usually builds across the cycle. |
| Side effects | SubQ and IM injections can sting. Slow push, site rotation, and bacteriostatic saline help reduce local reactions. |
| Regulatory status | Neither injectable NAD+ nor MOTS-c is FDA-approved for energy or metabolic indications. Oral NAD+ precursors: nicotinamide riboside (NR) is FDA GRAS; nicotinamide mononucleotide (NMN) regulatory status in the US is evolving. |
| Best stacked with | Semaglutide, Tirzepatide, Retatrutide for GLP-1 energy drag support. L-Carnitine for fatty acid transport into mitochondria. |
Which Peptides are Best for Energy?
Peptide therapy for energy focuses on repairing cellular function rather than providing a temporary stimulant "jolt" like caffeine. Depending on the root cause of your fatigue, different peptides target different pathways:
1. Mitochondrial Peptides (Capacity Builders)
These peptides work directly on the mitochondria to support ATP production.
- MOTS-c: Often called an "exercise mimetic," it improves insulin sensitivity and helps the body burn fat for sustained, jitter-free energy.
- SS-31 (Elamipretide): Targets the inner mitochondrial membrane, stabilizing cardiolipin to reduce oxidative stress—ideal for chronic fatigue.
2. Growth Hormone Secretagogues (Recovery)
These stimulate the pituitary gland to release natural growth hormone, improving deep sleep and metabolic efficiency.
- CJC-1295 & Ipamorelin: By enhancing the "repair and recover" phase of sleep, users report significantly higher daytime energy levels.
3. Cognitive Peptides (Mental Energy)
- Semax: Boosts neurotrophic factors (like BDNF) to sharpen focus and reduce mental fatigue without a crash.
- NAD+: While technically a coenzyme, it is frequently administered alongside peptides to support ATP production and mental clarity.
How NAD+ and MOTS-c Work Together (Fuel vs. Signal)
NAD+ and MOTS-c are two of the most prominent molecules in longevity science. While often discussed together, they play distinct but highly synergistic roles in cellular energy:
- NAD+ (The Fuel): A coenzyme required for mitochondria to convert food into ATP. It fuels sirtuins (longevity genes) and PARP enzymes (DNA repair).
- MOTS-c (The Signal): A mitochondrial-derived peptide (MDP) that acts as a metabolic messenger, telling the cell to increase glucose uptake and fat oxidation.
The Synergistic Positive Feedback Loop
When used together, NAD+ and MOTS-c create a feedback loop for mitochondrial support:
- Mitochondrial Biogenesis: MOTS-c signals the body to create new mitochondria, while NAD+ ensures these new mitochondria have the substrate needed to function.
- AMPK Activation: MOTS-c is a potent activator of AMPK (the "metabolic master switch"), which naturally increases intracellular NAD+ levels.
- Sirtuin Synergy: NAD+ is the required fuel for SIRT1. MOTS-c has been shown to enhance SIRT1 activity, making the available NAD+ more effective.
MOTS-c raises the ceiling on NAD+ recycling. Cells constantly recycle NAD+ — enzymes break it down, the salvage pathway rebuilds it. The rate-limiting enzyme in that rebuild is upregulated by MOTS-c (NAMPT upregulation², Wan 2023). MOTS-c raises the ceiling but doesn't create NAD+ from nothing — it accelerates recycling of whatever NAD+ is present. Supplemental NAD+ answers the substrate side of that equation.
SIRT1 converts the signal only when NAD+ is available. The enzyme that translates MOTS-c's signal into gene-expression changes (SIRT1⁵) requires NAD+ on hand to function. In depleted cells, the MOTS-c signal arrives but can't fully land — SIRT1 sits inactive without its cofactor. Co-administration is how the signal converts to adaptation.
For the single-compound mechanisms in depth, see the NAD+ guide and MOTS-c guide.
Who Benefits Most
The adaptation loop erodes at the signal end, the substrate end, or both. Identifying where the deficit sits predicts response.
Signal-side erosion. MOTS-c production declines with sedentary living, chronic metabolic stress, and age — but the decline correlates more with phenotype than with chronology. A 55-year-old who trains consistently and sleeps well often has MOTS-c levels that outperform a 32-year-old under chronic stress. The mechanism question is whether cellular demand is regularly signaling for adaptation; in sedentary patterns or compressed recovery windows, it isn't.
Substrate-side erosion. NAD+ depletes faster under inflammation and oxidative stress (e.g., illness, alcohol, sleep-deprivation), caloric deficit (when cells burn fat, each step of fat-to-ATP conversion consumes NAD+), and age (plasma NAD+ can fall sharply by age 60). Substrate-side collapse is why acute post-viral fatigue and aggressive fat-loss protocols hit the loop hardest — the cell has the signal but not the currency.
Four phenotypes present this pattern clinically
Adults with unexplained fatigue. The pattern is chronic — energy degrades over months, recovery lengthens, training or cognitive load that used to be sustainable now isn't. Baseline workup is clean. What's usually present is substrate-side erosion with signal-side decline in the background. NAD+ substrate replacement produces a felt shift almost immediately; MOTS-c builds and extends capacity across the rest of the cycle.
GLP-1 users experiencing energy drag. Semaglutide, tirzepatide, and retatrutide all drive aggressive fat mobilization and a steep caloric deficit. Converting that mobilized fat to ATP consumes NAD+ at every step of the fat-burning pathway (beta-oxidation). The loop gets stressed on both ends — the GLP-1 signals massive fuel-source change while NAD+ demand rises sharply against a baseline that was already declining.
Retatrutide adds a third receptor (glucagon) that directly tells the liver to burn more fat, which increases the NAD+ draw on the liver specifically. See the GLP-1 fatigue guide for the underlying mechanism and the retatrutide + NAD+ protocol for a retatrutide-specific implementation.
People with post-viral or long-COVID energy collapse. Viral illness drives acute NAD+ depletion through two competing demands: DNA-repair machinery kicks into overdrive, and immune cells burn through NAD+ to sustain inflammatory signaling. The loop collapses on the substrate side first, often with secondary signal-side erosion as deconditioning follows. Injectable NAD+ tends to produce the fastest felt effect in this phenotype — the acute deficit closes quickly. MOTS-c adds capacity-building over weeks as activity tolerance returns.
Active individuals hitting a ceiling with training. High-volume training accelerates both ends of the loop — MOTS-c production rises with demand, NAD+ consumption rises with the metabolic work. The ceiling people describe is usually the signal or substrate capacity catching up with the work they're producing. The pair raises both ceilings in parallel.
Non-responders
Primary cause is sleep deprivation or untreated thyroid dysfunction — neither compound fixes either, and response will feel absent. Advanced mitochondrial disease is a different problem than signal-and-fuel deficit. A rare genetic variant in MOTS-c (K14Q³) weakens the peptide's ability to bind its downstream target and may blunt response; clinical testing for the variant isn't yet routine.
Protocol
NAD+ is administered intramuscularly (IM) or subcutaneously (SubQ). MOTS-c is administered subcutaneously. The protocol runs 12 weeks, phased across loading, build, and maintenance.
| Phase | MOTS-c | NAD+ | Training / Lifestyle |
|---|---|---|---|
| Loading (weeks 1–2) | 5–10 mg SubQ 2–3× per week | 100–250 mg IM 2–3× per week | Electrolytes, zone-2 cardio |
| Build (weeks 3–6) | 5–10 mg SubQ 2–3× per week | 100–250 mg IM 2–3× per week | Resistance training, protein ≥ 1.6 g/kg |
| Maintain (weeks 7–12) | 5–10 mg SubQ 2× per week | 100–150 mg IM 1–3× per week | Sleep 7–9 hrs, glycine before bed |
Route practicalities. NAD+ IM is preferred for active rebuilds because it handles larger, sting-prone doses better. SubQ is acceptable, but stay lower and split larger doses because the shallow depot can burn or welt. MOTS-c SubQ is standard. For MOTS-c and SS-31-style injection-site reactivity, bacteriostatic saline (BAC water with 0.9% sodium chloride) is preferred over plain bacteriostatic water. Do not add salt manually to a vial.
Sequencing. Most readers run both compounds from week one. If NAD+ depletion is clearly acute — post-viral collapse, post-illness, recent high-dose GLP-1 titration — loading NAD+ one-week prior to starting MOTS-c is mechanistically defensible. This is a personal or clinical judgment.
Oral precursors are real secondary tools. NR or NMN can work as daily maintenance, after injectable loading, or for users who will not inject at all. IM NAD+ is preferred for stronger active support; oral precursors are steadier and easier to sustain. Full oral-vs-injection trade-off in the NAD+ guide.
Cycling. A 4-week washout after the 12 weeks is common, but not required — continuous maintenance at the Maintain-phase cadence is also documented, especially for sustained GLP-1 support.
Reconstitute correctly — see the reconstitution guide and peptide dosing calculator. MOTS-c at these doses is investigational. The dose range is anchored in exercise-pulse physiology, practitioner use, animal translation, and adjacent analog data, not a completed native-human outcome trial.
Timing and Pairing
Training-day MOTS-c, morning NAD+.
| Compound | Best time | Pair with | Avoid |
|---|---|---|---|
| MOTS-c | 30–60 min before training | Zone-2 cardio, moderate-intensity sessions | Max-effort intervals, exhaustive endurance bouts |
| NAD+ | Morning, after waking | Hydration, electrolytes | Evening dosing, late-day caffeine stacking |
What to Expect — Timeline
NAD+ is the fastest readout — substrate availability rises within hours, and the acute deficit starts closing immediately. MOTS-c acts mechanistically from the first dose, but mitochondrial build-out compounds over weeks.
| Window | What's happening | What you notice |
|---|---|---|
| Weeks 1–2 | NAD+ substrate replacement | Steadier baseline energy, fewer afternoon crashes |
| Weeks 3–6 | MOTS-c-driven mitochondrial biogenesis | Cardio easier, recovery faster, metabolic flexibility steadier |
| Weeks 7–8 | NAD+-dependent repair programs compound | Better sleep, mental clarity, stable deep energy |
| Weeks 9–12 | Consolidation | Higher training capacity, stable recovery under stress |
Side Effects and Safety
NAD+. Rapid IV push or high-concentration injections can cause flushing, chest pressure, nausea, headache, or transient blood pressure shifts. Slower administration, hydration, dilution, and smaller split doses reduce the burden. Users with heart failure, significant arrhythmia history, or recent cardiac events should use medical oversight before injectable NAD+, or use oral precursors instead.
MOTS-c. Injection-site reactions are the commonly reported issue at SubQ doses. The peptide is used at milligram scale and carries basic residues, so welts, warmth, itching, and stinging are usually local concentration / mast-cell effects rather than proof of contamination. Site rotation, true SubQ placement, slower push, and bacteriostatic saline usually help.
MTHFR carriers. MOTS-c inhibits the folate cycle, affecting both purine synthesis (AICAR → AMPK activation) and methylation (5-methyltetrahydrofolate and methionine both drop). MTHFR variants (C677T, A1298C) reduce the methyl-donor supply both pathways draw on, so MOTS-c can produce a sharper energy crash in carriers. The compound isn't off-limits for MTHFR carriers, but carriers should start at 2–3 mg weekly rather than 5–10 mg 2–3× weekly, and pair with methyl donors (methylfolate 400–800 mcg, methylcobalamin 1–2 mg, glycine 3 g) starting the week before the first dose.
Contraindications and cautions. Active malignancy is a theoretical concern given NAD+'s role in supporting cell metabolism broadly; the clinical literature on NAD+ / cancer interaction is mixed. Pregnancy or breastfeeding, uncontrolled hypertension, acute infection, and concurrent chemotherapy regimens that work by depleting NAD+ are additional reasons to pause and resolve before starting.
Neither MOTS-c nor injectable NAD+ is FDA-approved for energy or metabolic indications. That status is access and quality context, not the whole biological verdict. Native MOTS-c has weak patent economics and an active investigational path; injectable NAD+ sits in a fragmented compounding / clinic pathway while oral NR and NMN follow different commercial routes. Product quality, route, dose, and user phenotype matter.
FAQ
Can you take MOTS-c and NAD+ together?
Yes. MOTS-c signals adaptation and raises the speed limit on NAD+ recycling (NAMPT upregulation²). NAD+ supplementation provides the substrate that same system consumes. There is no documented interaction between the two. Wan 2023² and Mohtashami 2022⁵ anchor the direct mechanistic evidence; Pencina 2023⁶ provides the clinical case for why pairing matters rather than using either alone.
Inject separately — different sites, different syringes.
How much NAD+ should I take with MOTS-c?
Most active-support protocols use NAD+ 100–250 mg IM 2–3× per week, dropping toward 100–150 mg weekly or 1–3× per week for maintenance. SubQ can work, but keep the dose lower or split it because larger SubQ pushes are more likely to sting or welt. Pair with 5–10 mg MOTS-c SubQ 2–3× per week across the full cycle.
Oral NAD+ precursors — nicotinamide riboside (NR) at 300–1,000 mg/day or nicotinamide mononucleotide (NMN) at 250–500 mg/day — are secondary alternatives. They are better suited to maintenance, injection avoidance, and steady daily support than to a strong active rebuild.
When should I take NAD+ and MOTS-c?
MOTS-c 30–60 minutes before zone-2 cardio on training days. NAD+ in the morning. Avoid late-evening NAD+ dosing — it can extend alertness past the morning window through clock-linked enzyme activity (SIRT1⁵). Avoid pairing MOTS-c with max-effort or exhaustive single-bout sessions; moderate-intensity cardio raises MOTS-c in the brain's metabolic-control center (hypothalamus), exhaustive bouts do not (Kang 2021⁷).
I'm on a GLP-1 — can I add this protocol?
Yes, and this is a core use case for the pair. Semaglutide, tirzepatide, and retatrutide all drive aggressive fat mobilization that increases NAD+ demand — converting fat to ATP consumes NAD+ at every step. MOTS-c addresses the mitochondrial capacity strain, NAD+ keeps the fat-burning pathway running. Inject MOTS-c and NAD+ separately from the GLP-1 — different sites, different syringes. Retatrutide users are covered in depth at the retatrutide + NAD+ protocol.
How long until I feel it?
NAD+ shifts felt energy in the first 1–2 weeks as substrate replacement closes the acute deficit. MOTS-c-driven adaptation compounds across the rest of the cycle — see the timeline table for the week-by-week breakdown.
What if I don't notice any change by week 6?
Non-response at week 6 signals the phenotype isn't signal-and-fuel deficit. The most common explanations are sleep or thyroid dysfunction that wasn't the actual limiter, advanced mitochondrial damage beyond what this pair addresses, or K14Q MOTS-c variant blunting the signal. Revisit baseline labs, confirm sleep architecture, and consider whether structural mitochondrial intervention is indicated rather than extending the cycle.
Related Topics
- NAD+ Guide — complete NAD+ overview, injectable vs oral trade-offs, deep mechanism
- MOTS-c Guide — single-compound MOTS-c guide, mechanism, dosing detail
- Why GLP-1 Medications Make You Tired — the fatigue mechanism this pair addresses
- Retatrutide + NAD+ Protocol — retatrutide-specific implementation with NAD+ built in
- Reconstitution Guide — vial prep, bacteriostatic water selection, storage
- Peptide Dosing Calculator — reconstitution math per vial
SS-31 (elamipretide) targets mitochondrial membrane structure rather than signaling or substrate — relevant for Barth syndrome, cardiomyopathy with bioenergetic failure, and advanced mitochondrial disease contexts. See Mito Stack Protocol for the three-compound SS-31 + MOTS-c + NAD+ protocol.
References
¹ AMPK activation — MOTS-c inhibits the folate cycle, causing AICAR accumulation; AICAR activates AMPK. Folate-cycle inhibition also lowers 5-methyltetrahydrofolate and methionine, affecting methylation: Lee C, et al. Cell Metab 2015. doi:10.1016/j.cmet.2015.02.009; Wan W, et al. J Transl Med 2023. doi:10.1186/s12967-023-04128-0
² NAMPT upregulation — MOTS-c increases nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the NAD+ salvage pathway: Wan W, et al. J Transl Med 2023. doi:10.1186/s12967-023-04128-0
³ MOTS-c / CK2 binding — MOTS-c directly binds casein kinase 2; the K14Q variant has reduced binding and tracks with sarcopenia and type 2 diabetes risk in men: Kumagai H, et al. iScience 2024. doi:10.1016/j.isci.2024.108735
⁴ Age-independent physical capacity — MOTS-c improves physical performance in young (2 mo), middle-aged (12 mo), and old (22 mo) mice: Reynolds JC, et al. Nat Commun 2021. doi:10.1038/s41467-020-20790-0
⁵ NAD+ / SIRT1 coupling — MOTS-c elevates intracellular NAD+; SIRT1 deacetylation requires NAD+ availability: Mohtashami Z, et al. 2022. PMID:36482538
⁶ NAD+ precursor limitation in obese cohorts — nicotinamide riboside raised NAD+ but did not improve insulin resistance in obese middle-aged adults: Pencina KM, et al. J Clin Endocrinol Metab 2023. doi:10.1210/clinem/dgad027
⁷ Exercise-intensity dependence — moderate-intensity cardio increases hypothalamic MOTS-c; exhaustive single-bout sessions do not: Kang GM, et al. Cell Metab 2021. doi:10.1016/j.cmet.2021.01.003
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.